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Introduction: Historically, the incidence rate of cervical cancer (CC) in Eastern Europe and 
particularly in Bulgaria has constantly been higher than that in the other European countries. 
Adenosquamous carcinoma (ASC) is a rare histological subtype of CC with incidence rate of less 
than 6 per 100,000. We aimed to analyze the epidemiology and prognosis of all Bulgarian patients 
with ASC, registered at the Bulgarian National Cancer Registry (BNCR), and to compare patients’ 
characteristics and outcomes with those of patients, treated at a large specialized institution – the 
Department of Gynecologic Oncology, University Hospital in Pleven, Bulgaria.
Materials and Methods: This is a retrospective study of all cases of ASC, registered at the 
BNCR for a 10-year period of time. The Kaplan–Meier analysis with Log rank test was used 
to estimate the significant differences.
Results: The incidence rate of ASC was calculated as 3.2% of all CC registered in BNCR 
and 4.97% of all stage I patients, treated in our department. The 5-year overall survival (OS) 
rate of all patients with ASC tumors from the registry was 50.5%. A total of 171 (48.4%) of 
the patients had T1 tumors and a 5-year OS of 67.1%. Lymph node status was a significant 
prognostic factor for OS (p=0.001). Thirty-one patients with T1 tumors and ASC histology 
were treated in our department for the same period of time. Lymph node metastases were 
found in 10 of them (32.2%). The 5-year observed OS in ASC group was 74.19%.
Conclusion: The histological subtype of cancer of the uterine cervix has an impact on prognosis 
and should not be simply considered as a descriptive characteristic but a poor prognostic feature 
and should be an integral part of the decision-making in clinical management of patients.
Keywords: adenosquamous cervical carcinoma, incidence rate, clinical features, survival 
rate, prognosis
Introduction
Cervical carcinoma (CC) is both the fourth most common malignancy and cause of 
cancer-related death in women worldwide.1 The world age-standardized incidence 
rate (ASIR) of CC is 13.1 per 100,000, but there are big disparities according to the 
geographic region and the countries’ Human Development Index.2 Historically, 
the incidence rate of CC in Eastern Europe has constantly been higher than that 
in the other European countries.3 In Bulgaria for 2008 the ASIR is 21.9 per 100,000 
and for 2018 20.3 per 100 000.4
With the introduction of national screening programs and wider HPV vaccina-
tion, it is expected that both incidence and mortality will decrease by 2030. Still, 
there are examples where vaccination is not as effective as expected5 and the 
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screening is not equally effective for the prevention of 
different histological types of CC.6
Histological classification of CC distinguishes three 
major types – squamous cell carcinoma (SCC), adenocar-
cinoma (AC), and adenosquamous carcinoma (ASC). SCC 
is the most common type with 75–80% of the cases; AC 
and ASC together account for 15–20%.7 The prevalence of 
ASC varies within 3–10% of all CC7–10 and could be 
defined as a rare cancer (with an incidence rate of less 
than 6/100,000).9 There are specific pathological features 
that should be present in order to classify a tumor as an 
adenosquamous subtype: both malignant squamous and 
glandular components should be present in routine hema-
toxylin and eosin staining sections; use of special immu-
nohistochemical tests is not a mandatory condition.11 ASC 
should also be distinguished from the large-cell nonkera-
tinizing squamous cell carcinoma (LCSC) and the endo-
metrioid adenocarcinomas with squamous metaplasia in 
which the squamous component is benign.10
ASC was first described by Greene in 1963.12 In 2014, 
the World Health Organization (WHO) defined it as 
a malignant epithelial tumor, composed of a mixture of 
invasive adenocarcinoma and squamous cell carcinoma.13 
Still, the diagnosis of ASC can frequently be difficult. 
Recent analysis of the morphology of this subtype showed 
that 42% of the cases, primary diagnosed as ASC, were 
further reclassified.14 Besides the more complicated mor-
phology, ASCs also differ from SCCs and ACs in 
prognosis.15–18 In patients, undergoing surgical resection, 
followed by radiotherapy, ASC has shown intermediate 
prognosis between SCC and AC.19 Patients with a more 
advanced stage of ASC and AC and treated with definitive 
radiotherapy had worse outcomes, compared to SCC.20
We aimed to analyze the incidence rate and the prognos-
tic factors for overall survival (OS) among patients with ASC 
of the uterine cervix, registered at the Bulgarian National 
Cancer Registry and the patients, treated at a specialized 
oncogynecological institution – the Department of 
Gynaecologic Oncology, University Hospital in Pleven, 
Bulgaria for a period of 10 years (2007–2016).
Materials and Methods
Study of Population
This is a retrospective study of patients, diagnosed with 
ASC of the uterine cervix for a 10-years period of time 
between January 1st, 2007, and December 31st, 2016. 
A total of 10,994 women were diagnosed with cancer of 
the uterine cervix in Bulgaria and 353 (3.2%) of them 
were registered with ASC. An ethical committee approval 
(number 414-KEHИД/31.03.2016) was obtained from all 
patients who operated for cervical cancer at Department of 
Gynecologic Oncology, University Hospital—Pleven, 
Bulgaria for the study period. In this time period, no 
specific informed consent was used for patients from 
Medical University Pleven. All patients have signed 
a common informed consent in which they agree to pro-
vide their clinical and pathological data for research.
We divided patients into two groups:
● patients, registered in the Bulgarian National Cancer 
Registry (group 1);
● patients, treated at the Department of Gynaecologic 
Oncology, University Hospital in Pleven, Bulgaria 
(group 2).
Information and tumor characteristics of patients, treated 
at the Medical University Pleven (group 2), were obtained 
from the patients’ medical records. These characteristics 
for the group of patients from the BNCR (group 1) were 
extracted from the available data from the Registry. 
Standard follow-up procedures for both groups 1 and 2 
included clinical examinations, abdominal ultrasound, 
X-ray of the chest and blood tests every 3 months during 
the first 2 years, every six months between third and 
fifth year and then annually; annual whole-body CT 
screening.
Ethical committee for research in science of Medical 
University Pleven approval (#414-REC/31.03.2016) was 
obtained to perform the study.
Pathologic Characteristics
We collected data for age, tumor stage at diagnosis, tumor 
grade and TNM and FIGO classification. To classify and 
stage the tumors, the 6th edition of the TNM classification 
and FIGO classification 2009 was used. For group 2 
patients, pathological tests were done on archival paraffin- 
embedded tissues and the diagnoses were centrally re- 
confirmed based on H&E stained slides. Characteristics 
of patients, registered for the study period at the BNCR, 
are shown on Table 1.
ASC is rarely seen before the age of 40 and after the 
age of 70 years. Most commonly, it is diagnosed in 1st 
stage and with negative lymph nodes. Still for more than 
20% of patients, the status of the lymph nodes remains 
unknown according to data from the BNCR.
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For the same period of time at Medical University Pleven 
31 patients have been diagnosed with ASC of the uterine 
cervix. All cases were centrally reviewed to reconfirm 
diagnosis.
Statistical Analysis
All patients were followed up until April 1st, 2020. The survi-
val was estimated only in patients with only one cancer pri-
mary, who had survival longer than 1 month after diagnosis. 
Statistical analysis was performed by SPSS, version 24.0 
(SPSS, Inc., Chicago, IL). The Kaplan–Meier analysis with 
Log rank test was used to test for significance. Comparison 
between the two groups of patients was performed in R with 
ggplot2 library using t-test to investigate the significance. The 
significance level of the p value was set to 0.05 for a two-tailed 
analysis.
Results
During the 10 years of the study period, A total of 10,994 
women have been diagnosed with cancer of the uterine 
cervix in Bulgaria and were analyzed as group 1. In total, 
353 (3.2%) of them had ASC. Distribution of patients, 
according to the year of diagnosis and the prevalence of 
ASC is shown in Figure 1.
In group 1, the highest incidence rate of ASC is 
observed in women of age 50–64. ASC is commonly 
diagnosed in stage I, but more than half of the cases 
are diagnosed in advanced stage. In most cases, ASC 
has intermediate G2 differentiation, it is diagnosed with 
T1 tumor and negative lymph nodes. From all 353 
patients with ASC, 272 (77%) were surgically treated. 
In total, 182 (67%) of them were also treated with radio-
therapy. All 31 patients with ASC from our institution 
underwent surgical treatment and postoperative 
radiotherapy.
The median follow-up time for patients in both analysis 
groups, still alive at the time of this analysis, was 99.6 
months. The 5-years OS rate of all patients with ASC was 
50.5%. Among all registered cases of ASC, there were 171 
(48.4%) T1 tumors, and 100 (58.5%) of them have 
received both surgery and radiotherapy. The 5-year survi-
val rate calculated for patients followed up for more than 5 
years, was 67.1%. The median OS was not reached during 
the follow-up time. The lymph node status was 
a significant prognostic factor for OS (Figure 2, Log 
rank, p=0.001).
Among all T1 tumors from the Registry, 31 (8.8%) 
were surgically treated at the Department of Gynecologic 
Oncology, University Hospital in Pleven. Those are 4.97% 
of all FIGO stage I patients treated at our department and 
84% of all diagnosed ASC (in all stages). Among those 31 
patients, 20 (64.5%) were with FIGO stage IB1, and 11 
(35.5%) were with FIGO stage IB2. All have undergone 
radical hysterectomy with total pelvic lymph node dissec-
tion, followed by postoperative radiotherapy.
Characteristics of both patients registered at the 
National Registry and those treated in our department are 
given in Table 2.
When we compared the two groups of patients, those in 
group 2 who were treated at our institution were signifi-
cantly younger (p=0.021) with insignificantly lower tumor 
grade and less involved lymph nodes (Figure 3).
Further stratification of the patients in group 1, accord-
ing to tumor size, menopausal status and lymph nodes is 
shown in Table 3. This information was not available for 
patients registered in the National Registry.
More than half of the patients in group 2 are premeno-
pausal - 51.6% and 32.3% are postmenopausal. The most 
common size of the tumor is <2 cm (45.2%), followed by 
>4 cm (35.5%). Positive lymph nodes were detected in 
32.2%. The 5-year observed OS is 74.19%.
Table 1 Characteristics of Patients, Registered at the BNCR
Patients’ Characteristics N (%)
Age (mean) 54.8(26–88)
Age <40 50 14.2
40–69 246 69.7
>70 57 16.1
TNM Stage I 145 41.1
TNM Stage II 77 21.8
TNM Stage III 98 27.8
TNM Stage IV 23 6.5





Unkown T 9 2.5
N0 199 56.4
N1 71 20.1
Unkown N 83 23.5




Unknown G 140 39.7
Total 353 100.0
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The incidence of ASC among all patients from the National 
Cancer Registry is 3.2% and among patients with T1 treated 
at our department is 4.97%. Results are similar and in the 
range of the previously reported in the literature incidence 
rates. Diagnosis of ASC of the cervix might be difficult and 
often patients are reclassified after the first diagnosis.14 This 
may explain the difference in the incidence rate of ASC in 
our department and at the national level.
The observed 5-year OS of all 353 patients, diagnosed 
with ASC for the study period, is 50.5%, which is lower 
than the 5-year survival of all cervical carcinomas from 
the same period of time in Bulgaria. This gives us even 
indirect evidence that the prognosis patients with ASC of 
the uterine cervix is worse compared to the prognosis of 
patients with other histology.1
From all 31 patients surgically treated at the Department 
of Gynecologic Oncology, University Hospital in Pleven, 
Bulgaria, 20 (64.5%) were diagnosed with a tumor size 
<4 cm, and 14 (45.2%) were with tumors <2 cm. This 
evidence supports the concept that screening programs ben-
efit early detection of this carcinoma type, in contrast to AC. 
Metastatic lymph nodes were found in 10 patients (32.2%); 
in 6 (60%) of the cases, tumor size was >4 cm, and in 2 cases 
the tumors’ size was up to 2 cm and between 2 and 4 cm, 
respectively. This is in line with the fact that large tumor size 
increases the risk of lymphogenous metastasis. Five-year 
observed OS was estimated at 74.19%, which is 
a significantly lower rate than previously reported 92% 
Figure 1 Distribution of patients, according to the year of diagnosis and the prevalence of patients with ASC.
Figure 2 Overall survival according to stage, histologic type and lymph nodes status of all T1 patients registered at the Bulgarian National Cancer Registry for the study 
period.
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survival for the first stage.21 This is due to the fact that our 
patients were clinically diagnosed as stage I and subse-
quently restaged based on the identification of metastatic 
lymph nodes. Regardless of the small number of patients, 
we believe that ASC has a worse prognosis than SCC.
Ten (32.2%) of the patients from our Department have 
died during the follow-up time. Six of them have lymphatic 
metastases. In 4 of these cases, tumor size was >4 cm. In the 
group of deceased cases without lymphatic metastases, one 
case was with a tumor size >4 cm. From all patients who 
died during the follow up 7 were with lymphatic metastases 
and/or tumor size >4 cm, ie high-risk patients. All patients 
underwent postoperative radiotherapy. Despite that the sur-
vival rate is comparatively low, which makes it suggest that 
high-risk ASC patients should be treated more aggressively. 
Performing postoperative radiotherapy could be one of the 
reasons for the better outcome observed in our patients. The 
information for tumor size in millimeters is not available at 
the National Cancer Registry database and this could also 
affect survival differences observed between patients trea-
ted in our department and patients treated elsewhere. 
Clinical behavior of ASC, as demonstrated in our case 
series, confirms that ASC is to some extent closer to SCC, 
rather than to AC, but nonetheless has its own specific 
features, including worse prognosis and higher lymphogen-
ous metastatic potential.
Management in oncology is continuously evolving, with 
major advances in recent years. In the past, when surgery 
was the initial and frequently the only treatment modality, 
initial clinical staging of the disease was used to guide the 
management of patients. Other treatment modalities were 
referred to as either adjuvant or neoadjuvant as surgery was 
considered the only radical modality. In oncology, the biol-
ogy-driven approach is becoming more recognized and it is 
incorporated into the clinical strategy initially at diagnosis.
With the development of the technology, the imaging 
and the radiotherapy, and the introduction of systemic 
Table 2 Characteristics of Patients with Т1 ASC, Registered at 
the Bulgarian National Cancer Register and Patients Treated 






(Group 1) n (%)
UMHAT “D-r Georgi 
Stranski” Pleven 
(Group 2) n (%)
Age 51.9 (26–88) 48 (29–62)
N0 127 (74.3%) 21 (71%)
N1 25 (14.6%) 10 (22.6%)
Unknown N 19 (11.1%) 0 (0%)
G1 2 (1.2%) 0 (0%)
G2 69 (40.3%) 15 (48.4%)
G3 35 (20.5) 4 (12.9%)
Unknown G 65 (38%) 12 (38.7%)
Total 171 31
Figure 3 Comparison of patients, treated at UMHAT “D-r Georgi Stranski” Pleven with all other patients treated in Bulgaria for the study period by age (A), tumor grade 
(B) and lymph node involvement (C).
Table 3 Characteristics of Patients with T1 ASC, Treated at the 
Department of Gynecologic Oncology, University Hospital— 
Pleven, Bulgaria (2007–2016)




Size of primary tumor < 2 cm, n (%) 14 (45.2%)
Size of primary tumor 2–4 cm, n (%) 6 (19.3%)
Size of primary tumor > 4 cm, n (%) 11 (35.5%)
Positive lymph nodes (N+) 10 (32. 2%)
5-year observed survival 74.19%
Total 31
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treatment (chemo- and targeted therapy), prognosis of cervi-
cal cancer patients has improved. It has been established that 
different pathophysiology has a prognostic significance and 
thus may become an important factor in selecting patients 
for escalation or de-escalation of treatment. SCC histology is 
also a predictive factor of a better response to radiotherapy,22 
including in the palliative setting. Since AC and SCC have 
different precursor lesions,23 hence their management and 
response to therapy differ. It is considered that early vacci-
nation against HPV types, associated with higher risk for 
SCC, may contribute to a significant decrease in morbidity 
and thus decreased mortality for SCC.24 While anti-HPV- 
vaccination and screening programs, especially those includ-
ing liquid-based cytology and DNA-HPV tests lead to 
a decline in both morbidity and mortality due to SCC,25 
the same is not applicable to AC.
Both malignant glandular and squamous differentiation 
should be present for a tumor to be classified as adenosqua-
mous carcinoma. It should be distinguished from invasive 
stratified mucin-producing carcinoma, invasive stratified 
mucin-producing carcinoma with components, and HPV- 
associated adenocarcinomas with benign-appearing squamous 
metaplasia.14 Until 2014, when WHO introduced criteria for 
accurate diagnosis of ASC, some of the above tumor types and 
less distinct subtypes were classified as ASC type. Currently, 
ASC type group includes glassy cell carcinoma and mucoepi-
dermoid carcinoma.12,26–30 Data confirm the monoclonal ori-
gin of ASC, differentiating it as a distinct biological entity 
from both SCC and AC.31 Precursors to this carcinoma type 
are high-grade squamous intraepithelial lesion (HSIL) and 
adenocarcinoma in situ (ACIS) with frequent detection of 
Human Papilloma Virus types 16 and 18 related to them.10,32 
Vaccination is considered to reduce the incidence of ASC due 
to the presence of these particular HPV types. However, 
despite the increasing incidence of AC of the uterine cervix 
worldwide, the incidence of ASC does not change.6 
Additional evidence suggesting that ASC is closer to SCC 
than to AC, is that the efficacy of cervical cancer screening 
programs is similar for ASC and SCC and higher than that for 
AC.33,34
Furthermore, there are substantial uncertainties about the 
survival and prognosis of patients with ASC. Some research-
ers regard ASC in advanced stages with worse prognosis 
compared to AC as opposed to its earlier stages.17,35,36 Other 
studies do not show a definite difference in the 5-year 
survival of ASC, AC, and SCC of the cervix at the same 
stages and indicate that a worse prognosis is associated with 
a larger tumor size and metastatic lymph nodes.18,37 
Lymphovascular space invasion is more likely to occur in 
patients with ASC, but there is no significant difference in 
the prognosis between AC and ASC patients.38 In patients, 
treated with definitive radiotherapy, those with ASC had 
a worse prognosis than patients with SCC,8 but in cases 
when concurrent chemoradiotherapy was used, the prog-
nosis was similar in both groups.39 It is generally suggested 
that patients with ASC have worse prognosis than patients 
with SCC.40 Yokoi et al found that older age (>50) is an 
independent prognostic factor for reduced progression-free 
survival in patients with ASC histology.35
Conclusion
Adenosquamous carcinoma is a rare type of cervical can-
cer. Screening programs may benefit its early detection. 
Clinically, it is closer to SCC, rather than AC. Patients 
with locally advanced carcinomas and/or lymphogenous 
metastases should undergo more aggressive postoperative 
treatment as these factors reduce survival.
Currently, histology-driven approach is emerging as 
a clinical strategy, identifying high-risk patients. Disease 
stage is guiding the treatment strategy, but tumor biology 
is an additional important prognostic and potentially pre-
dictive factor. Escalation of treatment (eg chemoradiother-
apy) may improve the prognosis of patients with poor 
prognostic features, including adenosquamous histology. 
The pathophysiology of cervical carcinoma should no 
longer be a descriptive characteristic but rather be incor-
porated into the clinical management of patients.
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